ASX Penny Stocks To Watch In May 2025

In This Article:

The ASX200 is set to open more than one percent higher, reflecting a positive sentiment despite mixed performances on Wall Street, where investors are navigating company earnings and ongoing trade uncertainties. In such a fluctuating market landscape, identifying stocks with strong fundamentals becomes crucial for investors seeking stability and growth. Penny stocks, often representing smaller or newer companies, can offer surprising value when backed by solid financial foundations, making them an intriguing area to explore for potential opportunities.

Top 10 Penny Stocks In Australia

Name

Share Price

Market Cap

Financial Health Rating

Lindsay Australia (ASX:LAU)

A$0.705

A$223.61M

★★★★☆☆

CTI Logistics (ASX:CLX)

A$1.83

A$147.4M

★★★★☆☆

Accent Group (ASX:AX1)

A$1.95

A$1.17B

★★★★☆☆

EZZ Life Science Holdings (ASX:EZZ)

A$1.60

A$75.48M

★★★★★★

IVE Group (ASX:IGL)

A$2.68

A$413.21M

★★★★★☆

GTN (ASX:GTN)

A$0.615

A$117.51M

★★★★★★

GR Engineering Services (ASX:GNG)

A$2.76

A$461.9M

★★★★★★

Bisalloy Steel Group (ASX:BIS)

A$3.30

A$156.59M

★★★★★★

Regal Partners (ASX:RPL)

A$2.20

A$739.56M

★★★★★★

Navigator Global Investments (ASX:NGI)

A$1.745

A$855.19M

★★★★★☆

Click here to see the full list of 997 stocks from our ASX Penny Stocks screener.

Here's a peek at a few of the choices from the screener.

Optiscan Imaging

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Optiscan Imaging Limited develops, manufactures, and commercializes endomicroscopic digital imaging technology for medical and pre-clinical applications across Australia, Germany, China, and the United States with a market cap of A$108.59 million.

Operations: Optiscan Imaging generates revenue of A$4.96 million from its Confocal Microscopes segment.

Market Cap: A$108.59M

Optiscan Imaging, with a market cap of A$108.59 million, remains unprofitable despite generating A$4.96 million in revenue from its Confocal Microscopes segment. The company has seen earnings decline by 25.2% annually over the past five years and maintains a negative return on equity of -42.98%. Recent executive changes aim to enhance strategic execution and product development, including appointing Darius Ooi as CFO and Belinda Williamson as Chief Commercial Officer to strengthen sales efforts. Optiscan's cash runway exceeds one year, but its share price remains highly volatile compared to most Australian stocks.

ASX:OIL Revenue & Expenses Breakdown as at May 2025
ASX:OIL Revenue & Expenses Breakdown as at May 2025

Southern Cross Media Group

Simply Wall St Financial Health Rating: ★★★★☆☆